FDA Approval of neffy (Epinephrine Nasal Spray) — First Needle-Free Anaphylaxis Treatment
On August 9, 2024, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) as the first needle-free emergency treatment for Type I allergic reactions, including anaphylaxis, in adults and children weighing 30 kg (66 lb.) or more. Unlike traditional epinephrine auto-injectors such as EpiPen, neffy is administered intranasally. A 1 mg pediatric dose for patients weighing 15 to less than 30 kg was approved on March 5, 2025.
Find your state senator and state assembly/house member, then select one to address your letter.
Find all your legislators
Look up your U.S. Senators, U.S. Representatives, State Senators, and State Assembly/House members in one search — then pick who to write to.
Generate Your Coalition Letter
Pre-filled with this law's details — address it to your state legislator and send.
Coalition Supporters
First names only — privacy protectedNo advocates have joined yet. Be the first to support this law.
While we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.